Hiroaki Io

Dr. Hiroaki Io


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
MKMasako Kuwasawa-Iwasaki
Masako Kuwasawa-Iwasaki
HIHiroaki Io
Hiroaki Io
MMMasahiro Muto
Masahiro Muto
SISaki Ichikawa
Saki Ichikawa
KWKeiichi Wakabayashi
Keiichi Wakabayashi
YSYusuke Suzuki
Yusuke Suzuki
L-carnitine is an important factor in fatty acid metabolism, and carnitine deficiency is common in dialysis patients. This study evaluated whether l-carnitine supplementation improved muscle spasm, cardiac function, and renal anemia in dialysis patients. Eighty Japanese outpatients (62 hemodialysis (HD) patients and 18 peritoneal dialysis (PD) patients) received oral l-carnitine (600 mg/day) for 12 months; the HD patients further received intravenous l-carnitine injections (1000 mg three times/week) for 12 months, amounting to 24 months of treatment. Muscle spasm incidence was assessed using a questionnaire, and cardiac function was assessed using echocardiography. Baseline free carnitine concentrations were relatively low in patients who underwent dialysis for >4 years. Total carnitine serum concentration, free carnitine, and acylcarnitine significantly increased after oral l-carnitine treatment for 12 months, and after intravenous l-carnitine injection. There was no significant improvement in muscle spasms, although decreased muscle cramping after l-carnitine treatment was reported by 31% of patients who had undergone HD for >4 years. Hemoglobin concentrations increased significantly at 12 and 24 months in the HD group. Therefore, l-carnitine may be effective for reducing muscle cramping and improving hemoglobin levels in dialysis patients, especially those who have been undergoing dialysis for >4 years.

14 April 2014 in International Journal of Nephrology
Verified
Journal Article
Open access
PDF file
YIYuko Inami
Yuko Inami
CHChieko Hamada
Chieko Hamada
TSTakuya Seto
Takuya Seto
YHYoko Hotta
Yoko Hotta
SASeiki Aruga
Seiki Aruga
YTYasuhiko Tomino
Yasuhiko Tomino
Aim.Chronic kidney disease (CKD) represents endothelial dysfunction. Monocyte adhesion is recognized as the initial step of arteriosclerosis. Indoxyl sulfate (IS) is considered to be a risk factor for arteriosclerosis in CKD. Oral adsorbent AST-120 retards deterioration of renal function, reducing accumulation of IS. In the present study, we determined the monocyte adhesion in the adenine-induced uremic ratsin vivoand effects of AST-120 on the adhesion molecules.Methods. Twenty-four rats were divided into control, control+AST-120, adenine, and adenine+AST-120 groups. The number of monocytes adherent to the endothelium of thoracic aorta by imaging the entire endothelial surface and the mRNA expressions of adhesion and atherosclerosis-related molecules were examined on day 49. The mRNA expressions of ICAM-1 and VCAM-1 in human umbilical vein endothelial cells were also examined.Results. Adenine increased the number of adherent monocytes, and AST-120 suppressed the increase. The monocyte adhesion was related to serum creatinine and IS in sera. Overexpression of VCAM-1 and TGF-β1 mRNA in the arterial walls was observed in uremic rats. IS induced increase of the ICAM-1 and VCAM-1 mRNA expressionsin vitro.Conclusion. It appears that uremic condition introduces the monocyte adhesion to arterial wall and AST-120 might inhibit increasing of the monocyte adherence with CKD progression.

10 February 2017 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
RKReo Kanda
Reo Kanda
HIHiroaki Io
Hiroaki Io
JNJunichiro Nakata
Junichiro Nakata
YMYuko Makita
Yuko Makita
YSYu Sasaki
Yu Sasaki
YSYusuke Suzuki
Yusuke Suzuki

13 August 2010 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
HIHiroaki Io
Hiroaki Io
MMMayumi Matsumoto
Mayumi Matsumoto
KOKozue Okumura
Kozue Okumura
MSMichiko Sato
Michiko Sato
AMAtsumi Masuda
Atsumi Masuda
YTYasuhiko Tomino
Yasuhiko Tomino

13 January 2004 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
PDF file
HIHiroaki Io
Hiroaki Io
CHChieko Hamada
Chieko Hamada
MFMitsumine Fukui
Mitsumine Fukui
SHSatoshi Horikoshi
Satoshi Horikoshi
YTYasuhiko Tomino
Yasuhiko Tomino

30 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HIHiroaki Io
Hiroaki Io
JNJunichiro Nakata
Junichiro Nakata
HIHiroyuki Inoshita
Hiroyuki Inoshita
MIMasanori Ishizaka
Masanori Ishizaka
YTYasuhiko Tomino
Yasuhiko Tomino
YSYusuke Suzuki
Yusuke Suzuki
This study aimed to identify the ideal timing and setting for measuring blood pressure (BP) and determine whether the left ventricular mass index (LVMI) is an independent risk factor associated with increased cardiovascular events in hemodialysis (HD) patients. BP and LVMI were measured at baseline and at 6 and 12 months after HD initiation. BP was monitored and recorded at nine different time points, including before and after HD over a one-week period (HDBP). The mean BP measurement was calculated as the weekly averaged BP (WABP). LVMI was significantly correlated with home BP, in-office BP, HDBP, and WABP. Receiver operating characteristic analysis indicated that the cutoff LVMI value for cardiovascular events was 156 g/m2. LVMI and diabetes mellitus were significant influencing factors for cardiovascular events (hazards ratio (95% confidence interval): diabetes mellitus, 2.84 (1.17,7.45); LVMI > 156 g/m2, 2.86 (1.22,6.99)). Pre-HDBP, post-HDBP, and WABP were independently associated with higher LVMI in the follow-up periods. Hemoglobin and human atrial natriuretic peptide (hANP) levels were associated with LVMI beyond 12 months after HD initiation. Treatment of hypertension, overhydration based on hANP, and anemia may reduce the progression of LVMI and help identify HD patients at high risk for cardiovascular events.